SAG
SLN icon

SageView Advisory Group’s Silence Therapeutics SLN Stock Holding History

SageView Advisory Group’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11
Closed -$67 – 2125
2025
Q4 		$67 Buy
+11
New +$70 ﹤0.01% 2558

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

SageView Advisory Group's SLN Position: Q1 2026 in Review

SageView Advisory Group sold out of Silence Therapeutics (SLN) in Q1 2026, closing a stake of 11 shares — an estimated $67 sold.

SageView Advisory Group first reported a position in SLN in Q4 2025 and held it in 1 quarter. The position peaked at $67 in Q4 2025. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • SageView Advisory Group reported no remaining Silence Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 11 Silence Therapeutics shares in Q1 2026, an estimated $67.
  • SageView Advisory Group first reported a position in Silence Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Silence Therapeutics position peaked at $67 in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.